Molecular Tumor Boards: A Consensus Statement From the International Association for the Study of Lung Cancer
Authors:
- 7 July 2025
- journal article
- review article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 20 (11) , 1594-1614
Abstract
No abstract availableKeywords
Funding Information
- International Association for the Study of Lung Cancer
- National Cancer Institute
- National Institutes of Health (P30CA008748)
This publication has 77 references indexed in Scilit:
- ESMO Precision Oncology Working Group recommendations on the structure and quality indicators for molecular tumour boards in clinical practiceAnnals of Oncology, 2025
- Molecular Tumor Board of the University Medical Center Groningen (UMCG-MTB): outcome of patients with rare or complex mutational profiles receiving MTB-advised targeted therapyESMO Open, 2024
- Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working GroupAnnals of Oncology, 2024
- ESMO study on the availability and accessibility of biomolecular technologies in oncology in EuropeAnnals of Oncology, 2023
- Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) studyAnnals of Oncology, 2023
- Access and quality of biomarker testing for precision oncology in EuropeEuropean Journal of Cancer, 2022
- Uncommon EGFR mutations in non-small-cell lung cancer: A systematic literature review of prevalence and clinical outcomesCancer Epidemiology, 2022
- Detection of additional occult malignancy through profiling of ctDNA in late-stage cancer patientsAnnals of Oncology, 2021
- Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working GroupAnnals of Oncology, 2020
- Role ofCRTC1/MAML2Translocation in the Prognosis and Clinical Outcomes of Mucoepidermoid CarcinomaJAMA Otolaryngology–Head & Neck Surgery, 2016